Multiple mechanisms, multiple benefits: SGLT2 inhibition shows promise in lupus, gout

Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new data on how a class of drugs used in type 2 diabetes may also be beneficial in patients with lupus and gout.
This class, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, are typically prescribed to help improve glycemic control, as well as reduce the risks for major adverse cardiovascular events (MACE) and end-stage kidney disease, in patients with type 2 diabetes. However, many trials have also found SGLT2 inhibitors lower serum urate levels. In addition, a study presented

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.